AI-based Drug Design and Development in the Cloud

Cloud Pharmaceuticals is a clinical stage biopharmaceutical company that is a leader in the burgeoning field of Artificial Intelligence based drug development.  The company partners, designs, develops, and licenses novel drug compounds for a wide range of medical indications to the pharmaceutical, biotechnology and medical research markets.  Novel drugs are developed through vertical holdings, typically LLCs for specific therapeutic areas.  Cloud is developing a new class of poly-pharmacy therapeutics based on complex systems dynamics.  In addition, Cloud is launching a pre-competitive database of hits for the entire druggable genome by the end of 2020.  Cloud's objective is to own and liberally share the largest class of molecular IP ever developed.

The company launched in 2011 with a technology license from Duke University, and has since expanded through early stage funding arrangements from Microsoft, the National Science Foundation, and the University of Florida via its Gatorade royalty fund, and has established collaborations with Glaxosmithkline (“GSK”) and Fujitsu.  The company is currently raising its Series B round to further development of its leading programs and to accelerate discovery from the start to IND to 120 days.  Cloud's new accelerated approach is based on novel developments, including quantum computing technology developed with Fijitsu, an inhibitor/agonist database for the druggable genome, a complex systems dynamics approach to polypharmacy design, and reinforcement learning AI.